# CREWT Medical Systems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crewt-medical-systems

- Industry: Medical Devices & Equipment
- Headquarters: Tokyo, Japan
- Website: www.crewt.co.jp
- Total disclosed funding: $10M
- Latest round: Series E (Nov 1, 2021)
- Investors on record: 7

## About

Based in Japan, CREWT Medical Systems, Inc. develops advanced visual examination instruments aimed at improving glaucoma diagnostics, offering innovative solutions for healthcare professionals in the field of ophthalmology.CREWT Medical Systems, Inc. was founded in 2013 in Tokyo, Japan, focusing on the creation of medical devices for visual examination. The company has completed 5 deals, with the most recent funding round occurring on November 1, 2021, during which it raised JPY 320 million in Series E funding from Future Partners, supported by Fuyo General Lease and UTokyo Innovation Platform. This capital will aid in the expansion and mass production of its eye checkup device, along with development for the US market. CREWT's founder has a background in medical technology innovation, although specific prior ventures are not disclosed.CREWT Medical Systems, Inc. specializes in advanced visual examination devices for glaucoma diagnosis. Its flagship product, the AIMO, is recognized as the world’s first portable head-mounted medical device for visual field testing, which enhances assessment efficiency. The AIMO series has expanded to include the AIMO Plus CS for contrast sensitivity testing and the AIMO AM for screening facilities. In 2021, the company launched the imovifa, an upgraded vision evaluation device, alongside the imoscan for early detection, primarily used in Japan with potential in select Asian and European markets.CREWT Medical Systems, Inc. generates revenue through direct sales of its medical devices to healthcare institutions and professionals, using a B2B model. Products like the AIMO and imovifa are sold to medical facilities that integrate these devices into their diagnostic processes, with transactions involving upfront payments and ongoing support under separate agreements. The pricing reflects the advanced technology, ensuring accessibility while maintaining a sustainable revenue stream.In November 2021, CREWT Medical Systems, Inc. raised JPY 320 million in Series E funding, which will be utilized for the mass production of its eye checkup device and to develop products targeting the US market. The company plans to expand its product line and enhance its market presence in the upcoming years, with a focus on launching new innovations designed to meet global healthcare needs.

## Funding rounds

- Series E, Nov 1, 2021, $2.8M — Fuyo General Lease, UTokyo Innovation Platform, Future Partners
- Series E, Dec 28, 2018, $4.1M — Fuyo General Lease, UTokyo Innovation Platform
- Series C, Jun 12, 2015, $3.1M — Daiwa Corporate Investment, University of Tokyo Edge Capital Partners, SMBC Venture Capital, Regional Economy Vitalization Corporation of Japan (REVIC)

## Investors

- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series C
- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series C
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series C
- Regional Economy Vitalization Corporation of Japan (REVIC) — Series C
- Fuyo General Lease — Series E
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series E
- Future Partners — Series E